Traduction de «minutes range 5-15 » (Néerlandais → Français) :

2001 € Costs include additional time spent by GP offering, prescribing and following-up pharmacological treatment and retail prices of NRT or bupropion GP counselling occurs opportunistically during consultations for other diseases Counselling takes 10 minutes (range 5-15 minutes in sensitivity analysis).
2001 € Costs include additional time spent by GP offering, prescribing and following-up pharmacological treatment and retail prices of NRT or Buproprion GP counselling occurs opportunistically during consultations for other diseases Counselling takes 10 minutes (range 5-15 minutes in sensitivity analysis).

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

2000 € Minimal counselling by a GP consists of one or two consultations with a total length of 12 minutes, not provided as part of a consultation for other health reasons Minimal counselling+NRT is provided for a period of 8 weeks Intensive counselling+NRT is provided by a trained lung nurse for a total of 90 minutes after a brief advice from a lung physician, period of NRT is 12 weeks Intensive counselling+bupropion included intensive counselling as described above with bupropion for a period of 9 weeks Telephone counselling consists of one intake call of 30 minutes and six follow-up calls of each 15 minutes Costs of self-help materials was included One defined daily dose (DDD) equals 14 mg for NRT patches.
2000 € Minimal counselling by a GP consists of one or two consultations with a total length of 12 minutes, not provided as part of a consultation for other health reasons Minimal counselling+NRT is provided for a period of 8 weeks Intensive counselling+NRT is provided by a trained lung nurse for a total of 90 minutes after a brief advice from a lung physician, period of NRT is 12 weeks Intensive counselling+Buproprion included intensive counselling as described above with Buproprion for a period of 9 weeks Telephone counselling consists of one intake call of 30 minutes and six follow-up calls of each 15 minutes Costs of self-help materials was included One defined daily dose (DDD) equals 14 mg for NRT patches.

Lichaamsgewicht Aantal kauwtabletten per sterkte mg/kg range (kg) 57 mg 227 mg 3,0 – 5,5 0,5 5,2 – 9,5 5,6 – 10 1 5,7 – 10,2 10,1 – 15 1,5 5,7 – 8,5 15,1 – 22 0,5 5,2 – 7,5 22,1 – 45 1 5,0 – 10,3 45,1 – 68 1,5 5,0 – 7,5 68,1 – 90 2 5,0 – 6,7
57 mg 227 mg 3,0 – 5,5 0,5 5,2 – 9,5 5,6 – 10 1 5,7 – 10,2 10,1 – 15 1,5 5,7 – 8,5 15,1 – 22 0,5 5,2 – 7,5 22,1 – 45 1 5,0 – 10,3 45,1 – 68 1,5 5,0 – 7,5 68,1 – 90 2 5,0 – 6,7

Revestive werd bestudeerd bij 17 patiënten met SBS verdeeld over vijf behandelingsgroepen gebruik makend van doses van 0,03, 0,10 of 0,15 mg/kg teduglutide eenmaal per dag of 0,05 of 0,075 mg/kg tweemaal per dag in een 21 dagen durend open-label, multicenter, dose-ranging studie.
Revestive a été étudié lors d’une étude multicentrique ouverte de détermination de dose d’une durée de 21 jours chez 17 patients présentant un SIC, qui ont été assignés à un groupe de traitement sur cinq possibles traités par 0,03, 0,10 ou 0,15 mg/kg de teduglutide une fois par jour ou 0,05 ou 0,075 mg/kg deux fois par jour.

Bij een dosis range van 0,15 tot 3 g bedraagt de eliminatiehalfwaardetijd 6 tot 9 uur. De totale plasmaklaring bedraagt 0,6 – 1,4 l/u en de renale klaring bedraagt 0,3 – 0,7 l/u.
Elimination Dans une gamme de doses comprises entre 0,15 et 3 g, la demi-vie d’élimination varie de 6 à 9 heures, la clairance plasmatique totale est de 0,6 à 1,4 l/h et la clairance rénale est de 0,3 à 0,7 l/h.

De 740 geïncludeerde personen hadden een mediane leeftijd van 51 jaar (range: 18 tot 70); 60% van de personen was man; 21% had een body mass index ≥ 30 kg/m 2 ; 5% was zwart; 2% was Aziatisch; 85% had op baseline een HCV-RNA-niveau van ≥ 800.000 IE/ml; 15% had bridging fibrosis; 14% had cirrose; 57% had HCV-genotype 1a en 43% had HCV-genotype 1b.
Les 740 sujets inclus avaient un âge median de 51 ans (écart : 18 à70 ans) ; 60% des sujets étaient des hommes; 21% avaient un indice de masse corporelle ≥ 30 kg/m 2 ; 5% étaient noirs ; 2% étaient asiatiques ; 85% avaient un taux initial d’ARN du VHC ≥ 800,000 UI/ml ; 15% présentaient une fibrose sévère/fibrose en pont ; 14% avaient une cirrhose ; 57% étaient infectés par un VHC de génotype 1a et 43% par un VHC de génotype 1b.

Table 15: False positive and false negative mammography results (KCE table) Review Study Type of study Findings Range Mushlin et al, 1998 meta‐ analysis probability of false positive screening per screening 0,9 % to 6,5 % Olivotto et al, 1998 Hofvind et al, 2004 Elmore et al, 1998 Elmore et al, 1998 observational
Table 17: False positive and false negative mammography results (KCE table) Review Study Type of study Findings Range Mushlin et al, 1998 meta‐ analysis probability of false positive screening per screening 0,9 % to 6,5 % Olivotto et al, 1998 Hofvind et al, 2004 Elmore et al, 1998 Elmore et al, 1998 observational

AD 16 - - 1 AD 15 1 1 3 AD 14 5 7 4 AD 13 - 4 4 AD 12 32 33 34 AD 11 37 32 33 AD 10 39 34 34 AD 9 - 11 13 AD 8 36 32 32 AD 7 - 41 43 AD 6 - - 12 AD 5 - - - Totaal rang AD 150 195 213
AD 16 - - 1 AD 15 1 1 3 AD 14 5 7 4 AD 13 - 4 4 AD 12 32 33 34 AD 11 37 32 33 AD 10 39 34 34 AD 9 - 11 13 AD 8 36 32 32 AD 7 - 41 43 AD 6 - - 12 AD 5 - - - Total niveau AD 150 195 213

Voor Herceptin® bedraagt de verkoop in België 23.000 mg/100.000 inwoners, dit cijfer ligt 15% boven het E-13 cijfer en ligt in dezelfde range als Frankrijk en Zwitserland.
Pour Herceptin ® , les ventes se chiffrent en Belgique à 23.000 mg/100.000 habitants, chiffre qui se situe 15 % au-delà du chiffre de l’E-13, dans le même ordre de grandeur que la France et la Suisse.